Partner Content Partner Content Orphan medicines, advances, access and affordability LONDON, UNITED KINGDOM, April 19th 2017:
News Call for focus on NHS during snap election Pharma calls for focus on health service as nation goes to the polls.
News NICE rejects Opdivo in head and neck cancer – before it gain... England and Wales’ cost effectiveness watchdog NICE has rejected Opdivo for use against advanced head and neck cancer in draft guidance – before the drug has even been given final Euro
Views & Analysis How healthcare professionals engage NICE online NICE is reaching out and engaging more via social media.
News Hospitals should be fined for failing to innovate - report Government must get tough to encourage innovation, say peers.
News Charities unite to oppose NICE rare disease rules MPs to discuss controversial plan in special debate.
News MSD splits pharma business, hiving off oncology MSD is separating its cancer and non-cancer pharma operations as it prepares for the looming loss of patent protection for $31bn blockbuster Keytruda.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
